Shares of ImmunoGen, Inc. (NASDAQ:IMGN) have received an average rating of “Hold” from the eleven brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $7.30.

Several brokerages recently issued reports on IMGN. Zacks Investment Research upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Tuesday, October 31st. Leerink Swann reiterated a “buy” rating on shares of ImmunoGen in a research report on Tuesday, August 29th. BidaskClub upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Canaccord Genuity set a $8.00 price objective on shares of ImmunoGen and gave the stock a “buy” rating in a report on Monday, July 31st. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $5.00 price objective on shares of ImmunoGen in a report on Monday, September 25th.

In related news, VP Craig Barrows sold 14,600 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $6.95, for a total transaction of $101,470.00. Following the transaction, the vice president now owns 51,100 shares in the company, valued at $355,145. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.51% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new position in ImmunoGen in the third quarter worth approximately $143,000. Perceptive Advisors LLC bought a new position in ImmunoGen in the third quarter worth approximately $536,000. Allianz Asset Management GmbH bought a new position in ImmunoGen in the third quarter worth approximately $1,780,000. Schwab Charles Investment Management Inc. raised its position in ImmunoGen by 33.0% in the third quarter. Schwab Charles Investment Management Inc. now owns 441,445 shares of the biotechnology company’s stock worth $3,378,000 after acquiring an additional 109,547 shares during the period. Finally, Trexquant Investment LP raised its position in ImmunoGen by 220.0% in the third quarter. Trexquant Investment LP now owns 104,633 shares of the biotechnology company’s stock worth $800,000 after acquiring an additional 71,936 shares during the period. Institutional investors own 77.12% of the company’s stock.

ImmunoGen (NASDAQ:IMGN) opened at $5.70 on Tuesday. ImmunoGen has a 52-week low of $1.53 and a 52-week high of $8.84. The company has a debt-to-equity ratio of -0.03, a quick ratio of 2.78 and a current ratio of 2.81.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.42). The company had revenue of $8.50 million for the quarter, compared to the consensus estimate of $26.09 million. During the same quarter in the prior year, the company earned ($0.51) EPS. ImmunoGen’s revenue for the quarter was up 10.4% compared to the same quarter last year. research analysts forecast that ImmunoGen will post -0.98 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “ImmunoGen, Inc. (IMGN) Given Consensus Recommendation of “Hold” by Analysts” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/immunogen-inc-imgn-given-consensus-recommendation-of-hold-by-analysts/1716749.html.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.